Mimedx Group earnings were $6.2M for the trailing 12 months ending Jun 30, 2026, with -81.8% growth year over year. The latest MDXG earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$14.8M, up 36.6% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, MDXG reported annual earnings of $48.6M, with 14.5% growth. The next MDXG earnings date is Nov 4, 2026.
MDXG past earnings growth
How has MDXG's earnings growth performed historically?
On MDXG's earnings call on Jul 29, 2026, Mimedx Group (NASDAQ: MDXG) reported Q2 2026 earnings per share (EPS) of -$0.10, up 242.86% year over year. Total MDXG earnings for the quarter were -$14.84 million. In the same quarter last year, Mimedx Group's earnings per share (EPS) was $0.07.
The next MDXG earnings date is Nov 4, 2026. Add MDXG to your watchlist to be reminded of Mimedx Group's next earnings date.
What was MDXG's earnings growth in the past year?
As of Mimedx Group's earnings date in Jul 29, 2026, Mimedx Group's earnings has grown -81.82% year over year. This is 99.85 percentage points lower than the US Biotechnology industry earnings growth rate of 18.03%. MDXG earnings in the past year totalled $6.24 million.
Is Mimedx Group profitable or losing money?
As of the last Mimedx Group earnings report, Mimedx Group is currently profitable. Mimedx Group's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $6.24 million, a 80.61% decrease year over year.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.